Austrália - inglês - Department of Health (Therapeutic Goods Administration)

soul pattinson manufacturing pty ltd - allium sativum, quantity: 166.67 mg (equivalent: allium sativum, qty 2 g); ascorbic acid, quantity: 50 mg; sambucus nigra, quantity: 28.57 mg (equivalent: sambucus nigra, qty 200 mg); olea europaea, quantity: 200 mg (equivalent: olea europaea, qty 3.6 g); echinacea purpurea, quantity: 22.22 mg (equivalent: echinacea purpurea, qty 1 g); zinc citrate dihydrate, quantity: 15.56 mg (equivalent: zinc, qty 5 mg); handroanthus impetiginosus, quantity: 50 mg (equivalent: handroanthus impetiginosus, qty 200 mg) - capsule, hard - excipient ingredients: maltodextrin; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; purified water; gelatin; sodium lauryl sulfate - antioxidant/reduce free radicals formed in the body ; helps reduce/decrease free radical damage to body cells ; traditionally used in western herbal medicine to sudorific/diaphoretic/enhance/promote sweating/perspiration ; maintain/support general health and wellbeing ; maintain/support immune system health ; maintain/support healthy immune system function ; helps prevent dietary (state vitamin/mineral/nutrient) deficiency ; traditionally used in western herbal medicine to expectorant/clear respiratory tract mucous ; traditionally used in western herbal medicine to relieve symptoms of mild upper respiratory tract infections ; traditionally used in western herbal medicine to decrease/reduce/relieve symptoms of common cold ; maintain/support wound healing

Irlanda - inglês - HPRA (Health Products Regulatory Authority)

support pharma, s.l. - marbofloxacin - solution for injection - 40 mg/ml - antibacterial - porcine

União Europeia - inglês - EMA (European Medicines Agency)

teva pharma b.v. - docetaxel - carcinoma, non-small-cell lung; breast neoplasms; prostatic neoplasms - antineoplastic agents - breast cancerdocetaxel teva pharma monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.non-small-cell lung cancerdocetaxel teva pharma is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.docetaxel teva pharma in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.prostate cancerdocetaxel teva pharma in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.

União Europeia - inglês - EMA (European Medicines Agency)

teva pharma b.v. - pioglitazone hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - pioglitazone is indicated in the treatment of type-2 diabetes mellitus as monotherapy: , in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance. , pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance. after initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in hba1c). in patients who fail to show an adequate response, pioglitazone should be discontinued. in light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.,

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - erythromycin, quantity: 250 mg - capsule, enteric - excipient ingredients: povidone; monobasic potassium phosphate; lactose monohydrate; gelatin; carbon black; sunset yellow fcf; shellac; indigo carmine; purified water; cellacefate; erythrosine; diethyl phthalate - mayne pharma erythromycin is indicated in children and adults for the treatment of the following conditions: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes (group a beta haemolytic streptococci), streptococcus pneumoniae (diplococcus pneumoniae). lower respiratory tract infections of mild to moderate severity caused by streptococcus pyogenes (group a beta hemolytic streptococci), streptococcus pneumoniae (diplococcus pneumoniae), acute and chronic bronchitis, pneumonia. sinusitis caused by streptococcus pneumoniae, streptococcus pyogenes. otitis media due to streptococcus pneumoniae, streptococcus pyogenes. respiratory tract infections due to mycoplasma pneumonia (eaton's agent). skin, and skin structure infections of mild to moderate severity caused by streptococcus pyogenes and staphylococcus aureus (resistant staphylococci may emerge during treatment). bordetella pertussis: erythromycin produces early elimination of the causative organism from the nasopharynx although the clinical course of the disease is not altered; therapeutic doses should be continued for at least 10 days. diphtheria: as an adjunct to antitoxin infections due to corynebacterium diphtheriae, to prevent establishment of carriers and to eradicate the organism in carriers. erythrasma: in the treatment of infections due to corynebacterium minutissimum. infections due to listera monocytogenes. non-gonococcal urethritis: chlamydia trachomatis and ureaplasma urealyticum have been shown to be sensitive to erythromycin and clinical studies have demonstrated its efficacy in urethritis due to these organisms. a minimum of 10 days therapy appears to be required. chlamydia trachomatis infection (excluding non-gonococcal urethritis): erythromycin has been shown to be effective in the treatment of trachoma or inclusion-body conjunctivitis and pneumonia in infants caused by chlamydia trachomatis. campylobacter fetus (subspecies) jejuni: infections due to this organism when antibiotic therapy is indicated. primary syphilis caused by treponema pallidum: erythromycin (oral forms only) is an alternative choice of treatment for primary syphilis in patients allergic to the penicillins. in the treatment of primary syphilis, spinal fluid should be examined before treatment and as part of the followup after therapy. legionnaires' disease caused by legionella pneumophila: although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating legionnaires' disease. prevention of initial attacks of rheumatic fever: penicillin is considered by the american heart association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of group a beta - haemolytic streptococcal infections of the upper respiratory tract e.g. tonsillitis or pharyngitis). erythromycin is indicated for the treatment of penicillin allergic patients. a therapeutic dose should be administered for 10 days. prevention of recurrent attacks of rheumatic fever: penicillin or sulphonamides are considered by the american heart association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. in patients who are allergic to penicillin and sulphonamides, oral erythromycin is recommended by the american heart association in the long term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). prevention of bacterial endocarditis: although no controlled clinical efficacy trials have been conducted, oral erythromycin has been suggested by the american heart association and the american dental association in a regimen for prophylaxis against bacterial endocarditis in patients sensitive to penicillin who have congenital heart disease, or rheumatic or other acquired valvular heart disease when they undergo dental or surgical procedures of the upper respiratory tract. erythromycin is not suitable prior to genitourinary or gastrointestinal tract surgery.

Israel - inglês - Ministry of Health

mbi pharma ltd., israel - dexamethasone phosphate ( as sodium phosphate ) - solution for injection / infusion - dexamethasone phosphate ( as sodium phosphate ) 4 mg/ml - dexamethasone - dexamethasone kern pharma is indicated in the treatment of:• endocrine diseases such as nonsuppurative thyroiditis, hypercalcaemia associated with cancer and congenital adrenal hyperplasia.• allergy: severe or disabling allergic conditions resistant to conventional treatments, as in: bronchial asthma, contact or atopical dermatitis, seasonal or perennial allergic rhinitis, hypersensitivity reactions to drugs.• ophtalmic: serious inflammatory and allergic processes, acute and chronic, affecting the eyes, such as: iritis and iridocyclitis, chorioretinitis, choroiditis and diffuse posterior uveitis, optical neuritis, allergic conjunctivitis, allergic marginal corneal ulcers.• inflammatory bowel dis.: systemic treatment in exacerbations of ulcerative colitis and regional enteritis.• dermatological diseases (pemphigus, stevens johnson syndrome, exfoliative dermatitis, severe psoriasis and mycosis fungoides) • respiratory diseases (symptomatic sarcoidosis, berylliosis, loeffler's syndrome)• haematological: acquired )autoimmune( haemolytic anaemia, idiopathic thrombocytopenic purpura in adult, pure red cell aplasia• nephrotic syndrome of the idioplathic type or that due to lupus erythematosus• cerebral edema caused by brain tumor, neurosurgery, brain abscess, bacterial meningitis• collagen diseases: active rheumatoid arthritis with severe progressive course, fast destructive remitting forms and / or extra-articular manifestations, juvenile idiopathic arthritis with severe systemic-onset form (still's disease) or locally with no control, rheumatic fever with carditis, dermatomyositis, polymyositis, sle, temporal arteritis.• infectious diseases: bacterial meningitis – adjunct to antibiotics in suspected pneumococcal meningitis and tb meningitis. severe infectious diseases with toxic states (eg tuberculosis, typhoid, brucellosis;. only with simultaneous anti-infective therapy)• fetal lung maturation• chemotherapy – associated nausea and vomiting• multiple myeloma – part of chemotherapy protocols (eg vad)• prevention and treatment of acute mountain sickness/hace

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

soul pattinson manufacturing pty ltd - ferrous fumarate, quantity: 15.2 mg (equivalent: iron, qty 5 mg); nicotinamide, quantity: 75 mg; manganese amino acid chelate, quantity: 5 mg (equivalent: manganese, qty 1 mg); zinc amino acid chelate, quantity: 75 mg (equivalent: zinc, qty 15 mg); panax ginseng, quantity: 5 mg (equivalent: panax ginseng, qty 50 mg); calcium pantothenate, quantity: 75 mg (equivalent: pantothenic acid, qty 68.7 mg); colecalciferol, quantity: 0.0125 mg; d-alpha-tocopheryl acid succinate, quantity: 41.32 mg; ascorbic acid, quantity: 100 mg; thiamine hydrochloride, quantity: 75 mg; pyridoxine hydrochloride, quantity: 75 mg (equivalent: pyridoxine, qty 61.7 mg); cyanocobalamin, quantity: 50 microgram; inositol, quantity: 20 mg; potassium iodide, quantity: 130.83 microgram (equivalent: iodine, qty 100 microgram); selenomethionine, quantity: 372.2 microgram (equivalent: selenium, qty 149.9 microgram); magnesium oxide, quantity: 82.95 mg (equivalent: magnesium, qty 50.02 mg); potassium citrate, quantity: 27.62 mg (equivalent: potassium, qty 9.99 mg); chromium picolinate, quantity: 362.96 microgram (equivalent: chromium, qty 45.12 microgram); riboflavin, quantity: 75 mg; citrus bioflavonoids extract, quantity: 50 mg; calcium citrate tetrahydrate, quantity: 190.48 mg (equivalent: calcium, qty 40.15 mg) - capsule, hard - excipient ingredients: maltodextrin; calcium hydrogen phosphate; magnesium stearate; colloidal anhydrous silica; calcium hydrogen phosphate dihydrate; microcrystalline cellulose; mono- and di- glycerides; starch sodium octenyl succinate; sodium ascorbate; silicon dioxide; dl-alpha-tocopherol; sucrose; medium chain triglycerides; titanium dioxide; sorbitan monolaurate; potable water; gelatin; sodium lauryl sulfate - antioxidant/reduce free radicals formed in the body ; helps reduce/decrease free radical damage to body cells ; maintain/support energy levels ; helps convert (state food) into energy ; maintain/support energy production ; maintain/support healthy eye function ; maintain/support eye health ; maintain/support healthy eyesight/vision ; maintain/support general health and wellbeing ; maintain/support hair growth ; maintain/support connective tissue health ; aid/assist/helps connective tissue production/formation ; helps maintain/support transport of oxygen in the body ; aid/assist/helps oxygen transport to body tissues ; maintain/support healthy cardiovascular system function ; maintain/support heart health ; maintain/support immune system health ; maintain/support healthy immune system function ; maintain/support muscle function ; maintain/support healthy neuromuscular system/function ; aid/assist/helps glucose/sugar/carbohydrate metabolism ; aid/assist/helps protein synthesis in the body ; helps prevent dietary (state vitamin/mineral/nutrient) deficiency ; aid/assist/helps metabolism of (state vitamin/mineral/nutrient) ; aids/assists the body to cope with environmental stress ; support healthy stress response in the body ; maintain/support cognitive function/mental function ; maintain/support nerve conduction ; aid/assist/helps synthesis of neurotransmitters ; maintain/support nervous system health ; maintain/support nervous system function ; maintain/support preconception health ; maintain/support reproductive system health ; maintain/support healthy reproductive hormones ; maintain/support sperm health ; maintain/support sperm motility ; maintain/support sperm production ; maintain/support testosterone level

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

soul pattinson manufacturing pty ltd - manganese amino acid chelate, quantity: 17.5 mg (equivalent: manganese, qty 1.75 mg); zinc amino acid chelate, quantity: 37.5 mg (equivalent: zinc, qty 7.5 mg); colecalciferol, quantity: 0.025 mg; heavy magnesium oxide, quantity: 83.5 mg (equivalent: magnesium, qty 50.36 mg); calcium carbonate, quantity: 1.5 g (equivalent: calcium, qty 600.6 mg); copper gluconate, quantity: 3.57 mg (equivalent: copper, qty 500 microgram) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; hypromellose; maltodextrin; microcrystalline cellulose; crospovidone; acacia; titanium dioxide; macrogol 8000; maize starch; silicon dioxide; dl-alpha-tocopherol; sucrose; medium chain triglycerides - antioxidant/reduce free radicals formed in the body ; helps reduce/decrease free radical damage to body cells ; maintain/support collagen formation ; maintain/support collagen health ; maintain/support energy production ; maintain/support healthy eye function ; maintain/support eye health ; maintain/support healthy eyesight/vision ; maintain/support general health and wellbeing ; maintain/support hair health ; maintain/support healthy teeth ; maintain/support nail health/strength/thickness ; maintain/support connective tissue health ; aid/assist/helps connective tissue production/formation ; maintain/support bone health ; aids/assists healthy bone development/growth/building ; maintain/support bone mass/density/integrity ; maintain/support bone strength ; help maintain/support bone mineralisation ; a diet deficient in calcium can lead to osteoporosis in later life. calcium may help prevent osteoporosis when dietary intake is inadequate ; vitamin d helps calcium absorption (or words of like intent) and a diet deficient in calcium can lead to osteoporosis in later life ; aid/assist healthy red blood cell production ; helps maintain/support haemoglobin formation/synthesis ; maintain/support healthy cardiovascular system function ; maintain/support heart health ; maintain/support blood vessel health ; maintain/support healthy digestive system function ; maintain/support immune system health ; maintain/support healthy immune system function ; maintain/support healthy muscle contraction function ; maintain/support muscle function ; maintain/support healthy neuromuscular system/function ; aid/assist/helps glucose/sugar/carbohydrate metabolism ; aid/assist/helps protein synthesis in the body ; maintain/support absorption of dietary (state vitamin/mineral/nutrient) ; maintain/support (state vitamin/mineral/nutrient) levels in the body ; helps prevent dietary (state vitamin/mineral/nutrient) deficiency ; aid/assist/helps metabolism of (state vitamin/mineral/nutrient) ; maintain/support cognitive function/mental function ; maintain/support nerve conduction ; maintain/support neuromuscular function ; maintain/support nervous system health ; maintain/support nervous system function ; maintain/support female reproductive system health ; maintain/support preconception health ; maintain/support reproductive system health ; maintain/support healthy reproductive hormones ; maintain/support sperm health ; maintain/support sperm production ; maintain/support testosterone level ; maintain/support skin health ; maintain/support skin integrity/structure ; maintain/support skin regeneration ; maintain/support wound healing

Malta - inglês - Medicines Authority

pharmazac, s.a. 31 naousis str., 104 47, athens,, greece - sugammadex - solution for injection - sugammadex 200 mg - all other therapeutic products

Malta - inglês - Medicines Authority

pharmazac, s.a. 31 naousis str., 104 47, athens,, greece - sugammadex - solution for injection - sugammadex 500 mg - all other therapeutic products